IP Verse

Multiplex Assay For Improved Scoring Of Tumor Tissues Stained For Pd-L1 - EP3149481

The patent EP3149481 was granted to Ventana Medical Systems on Jan 9, 2019. The application was originally filed on May 29, 2015 under application number EP15727610A. The patent is currently recorded with a legal status of "Revoked".

EP3149481

VENTANA MEDICAL SYSTEMS
Application Number
EP15727610A
Filing Date
May 29, 2015
Status
Revoked
Oct 31, 2023
Publication Date
Jan 9, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

CMS CAMERON MCKENNA NABARRO OLSWANGOct 9, 2019CMS CAMERON MCKENNA NABARRO OLSWANG -

Patent Citations (4) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
OPPOSITIONUS2006083744
OPPOSITIONWO2007082154
OPPOSITIONWO2013173223
OPPOSITIONWO2015061668

Non-Patent Literature (NPL) Citations (12) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- Elmer Perkin, "MULTIPLEX TISSUE BIOMARKERS IN CONTEXT", (20140506), URL: https://www.perkinelmer.com/lab-solutions/resources/docs/FLY_Opal-Multiplex-Staining.pdf, (20171208), XP055433617
EXAMINATION- R C Lloyd ET AL, "Phenotyping immune cells in-situ. An investigation of the spatial heterogeneity of specific immune cell phenotypes in the tumour microenvironment", (20140308), URL: www.poster-submission.com/cdrom/download_poster/37/27814/1062P, (20171211), XP055433943
EXAMINATION- S. LYFORD-PIKE ET AL, "Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma", CANCER RESEARCH, (20130103), vol. 73, no. 6, doi:10.1158/0008-5472.CAN-12-2384, ISSN 0008-5472, pages 1733 - 1741, XP055179352
INTERNATIONAL-SEARCH-REPORT- GHEBEH HAZEM ET AL, "FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy", BMC CANCER, BIOMED CENTRAL, LONDON, GB, (20080223), vol. 8, no. 1, ISSN 1471-2407, page 57, XP021034690 [A] 1-25 * the whole document * * In particular: Title; Abstract; Methods section, immunohistochemistry, part (b). *
INTERNATIONAL-SEARCH-REPORT- J Powderly ET AL, "Biomarkers and Associations With the Clinical Activity of PD-L1 Blockade in a MPDL3280A Study", (20130101), URL: http://carolinabiooncology.org/wp-content/uploads/ASCO-2013-Presentation-Anti-PDL-1-Biomarkers.pdf, (20150813), XP055207634 [A] 1-25 * the whole document * * In particular: slides 9-14 *
INTERNATIONAL-SEARCH-REPORT- YOSHIKO IWAI ET AL, "PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.", INTERNATIONAL IMMUNOLOGY, (20050201), vol. 17, no. 2, doi:dxh194, ISSN 0953-8178, pages 133 - 44, XP055142463 [A] 1-25 * the whole document * * In particular: p. 135, histology; Fig. 2D *
INTERNATIONAL-SEARCH-REPORT- O. K. AFANASIEV ET AL, "Merkel Polyomavirus-Specific T Cells Fluctuate with Merkel Cell Carcinoma Burden and Express Therapeutically Targetable PD-1 and Tim-3 Exhaustion Markers", CLINICAL CANCER RESEARCH, (20131001), vol. 19, no. 19, doi:10.1158/1078-0432.CCR-13-0035, ISSN 1078-0432, pages 5351 - 5360, XP055207749 [A] 1-25 * the whole document * * In particular: Title; Abstract; p. 5352, immunohistochemistry; Fig. 6. *
INTERNATIONAL-SEARCH-REPORT- GHEBEH H ET AL, "The B7-H1 (PD-L1) T lymphocyte-stimulatory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors", NEOPLASIA, NEOPLASIA PRESS, ANN ARBOR, MI, US, (20060301), vol. 8, no. 3, doi:10.1593/NEO.05733, ISSN 1522-8002, pages 190 - 198, XP008091677 [X] 1-25 * the whole document * * In particular: Title; Abstract; Materials and methods section, hystochemistry. *
OPPOSITION- DEBRA HAWES et al., "Immunohistochemistry", Modern surgical pathology, (20090000), pages 48 - 70, XP055624588
OPPOSITION- PERKINELMER, "get more insight from tissue with opal multiplex staining", Multiplex Tissue Biomarkers in Context, (20140506), URL: https://www.perkinelmer.com/lab- solution s/resources/docs/FLY_Opal-Multiplex-Stain ing. pdf, XP055650650
OPPOSITION- TAUBE et al., "Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-L1 therapy", Clin Cancer Res, (20140000), vol. 20, no. 19, doi:10.1158/1078-0432.CCR-13-3271, pages 5064 - 74, XP055291958
OPPOSITION- GHEBEH et al., "The B7-H7 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors", Neoplasia, (20060000), vol. 8, no. 3, doi:10.1593/neo.05733, pages 190 - 198, XP008091677

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents